With compounders out of the way, Lilly and Novo go after each other

With compounders out of the way, Lilly and Novo go after each other

The two obesity leaders are pulling on all levers to stay on top of the market.

FDA accepts filing application for oral semaglutide 25mg

Novo Nordisk has announced that the FDA accepted its New Drug Application (NDA) submission for an investigational once-daily, 25mg oral formulation of Wegovy (semaglutide) for chronic weight management in adults living with obesity or overweight with one or more comorbid conditions and to reduce the risk of major adverse cardiovascular events (MACE) in adults with overweight or obesity and established cardiovascular disease. If approved, Wegovy …